RNA delivery technology, Immune Activators (Adjuvants)
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
96
NCT05132907
Safety and Immunogenicity of HDT-301 Targeting a SARS-CoV-2 Variant Spike Protein
Phase: Phase 1
Role: Lead Sponsor
Start: Jan 24, 2022
Completion: May 30, 2024
NCT06799013
Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against Crimean-Congo Hemorrhagic Fever
Start: Jul 10, 2025
Completion: Jul 31, 2027
Loading map...